Home Cart Sign in  
Chemical Structure| 34367-04-9 Chemical Structure| 34367-04-9

Structure of Ginsenoside Ro
CAS No.: 34367-04-9

Chemical Structure| 34367-04-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ginsenoside Ro, a natural product isolated and purified from the root of Panax ginseng C. A. Mey., is reported to have anti-infllammtory, anti-hepatitic activities, and showed inhibitory activity against 5αR with IC(50) value of 259.4 μm

Synonyms: Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ginsenoside Ro

CAS No. :34367-04-9
Formula : C48H76O19
M.W : 957.11
SMILES Code : O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](O[C@H](C(O)=O)[C@@H](O)[C@@H]6O)([H])[C@@H]6O[C@]([C@@H]([C@@H](O)[C@@H]7O)O)([H])O[C@@H]7CO)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]8O)O)O[C@@H]8CO
Synonyms :
Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V
MDL No. :MFCD01732056
InChI Key :NFZYDZXHKFHPGA-QQHDHSITSA-N
Pubchem ID :11815492

Safety of Ginsenoside Ro

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Related Pathways of Ginsenoside Ro

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
EC-9706 cells 50 μM 12 hours Ro treatment resulted in a dramatic accumulation of LC3B-II, indicating inhibition of autophagic flux. Autophagy. 2016 Sep;12(9):1593-613
TE-1 cells 50 μM 12 hours Ro treatment resulted in a dramatic accumulation of LC3B-II, indicating inhibition of autophagic flux. Autophagy. 2016 Sep;12(9):1593-613
ECA-109 cells 50 μM 12 hours Ro blocked the autophagosome-lysosome fusion process by raising lysosomal pH and attenuating lysosomal cathepsin activity, resulting in the accumulation of the autophagosome marker MAP1LC3B/LC3B and SQSTM1/p62. Autophagy. 2016 Sep;12(9):1593-613
RAW264.7 macrophages 10-400 μM 24 hours To assess the effect of Ginsenoside Ro on cell viability. Results showed that Ginsenoside Ro was non-toxic to RAW264.7 cells at concentrations ranging from 10-400 μM. J Ginseng Res. 2022 Jan;46(1):156-166
human platelets 100-300 μM 5 min Inhibited fibrinogen binding to αIIb/β3 via cAMP-dependent phosphorylation of VASP (Ser157) J Ginseng Res. 2016 Oct;40(4):359-365
human platelets 50-300 μM 3 min Inhibited thrombin-induced platelet aggregation in a dose-dependent manner by reducing light transmission J Ginseng Res. 2016 Oct;40(4):359-365
human platelets 50-300 μM 3 minutes To investigate the effect of G-Ro on thrombin-induced platelet aggregation and TXA2 production. G-Ro dose-dependently inhibited platelet aggregation and TXB2 levels. J Ginseng Res. 2019 Apr;43(2):236-241
Raw 264.7 mouse macrophage cells 50 μM, 100 μM, 200 μM 1 h pretreatment followed by 24 h LPS treatment GRo significantly increased cell viability, reduced ROS and NO levels, decreased expression of inflammatory cytokines iNOS and COX-2, and exerted anti-inflammatory effects via upregulation of HO-1 J Ginseng Res. 2015 Oct;39(4):365-70

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LPS-induced acute lung injury model Oral 20, 40, 80 mg/kg Consecutive five days To evaluate the protective effect of Ginsenoside Ro on LPS-induced acute lung injury. Results showed that Ginsenoside Ro significantly attenuated pathological damage in lung tissue and reduced the expression levels of TNF-α, IL-6, and IL-1β. J Ginseng Res. 2022 Jan;46(1):156-166
BALB/c mice Lethal HVJ infection model Oral 1 mg/mouse Administered 3, 2, and 1 day before infection Ginsenoside Ro showed significant protective activity against HVJ infection with a survival rate of 42.8%. J Ginseng Res. 2013 Mar;37(1):80-6

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.04mL

0.21mL

0.10mL

5.22mL

1.04mL

0.52mL

10.45mL

2.09mL

1.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories